Historical Valuation
Rallybio Corp (RLYB) is now in the Fair zone, suggesting that its current forward PS ratio of 224.15 is considered Fairly compared with the five-year average of -2.35. The fair price of Rallybio Corp (RLYB) is between 0.07 to 0.84 according to relative valuation methord.
Relative Value
Fair Zone
0.07-0.84
Current Price：0.71
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Rallybio Corp (RLYB) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 0.79 , the current P/B ratio is approximately -40.27% higher. Relative to its 5-year average P/B ratio of 1.09, the current P/B ratio is about -56.71% higher. Rallybio Corp (RLYB) has a Forward Free Cash Flow (FCF) yield of approximately -117.13%. Compared to its 3-year average FCF yield of -111.81%, the current FCF yield is approximately 4.76% lower. Relative to its 5-year average FCF yield of -79.70% , the current FCF yield is about 46.96% lower.
P/B
Median3y
0.79
Median5y
1.09
FCF Yield
Median3y
-111.81
Median5y
-79.70
Competitors Valuation Multiple
AI Analysis for RLYB
The average P/S ratio for RLYB competitors is 52.79, providing a benchmark for relative valuation. Rallybio Corp Corp (RLYB.O) exhibits a P/S ratio of 224.15, which is 324.6% above the industry average. Given its robust revenue growth of -29.10%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RLYB
1Y
3Y
5Y
Market capitalization of RLYB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RLYB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RLYB currently overvalued or undervalued?
Rallybio Corp (RLYB) is now in the Fair zone, suggesting that its current forward PS ratio of 224.15 is considered Fairly compared with the five-year average of -2.35. The fair price of Rallybio Corp (RLYB) is between 0.07 to 0.84 according to relative valuation methord.
What is Rallybio Corp (RLYB) fair value?
RLYB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Rallybio Corp (RLYB) is between 0.07 to 0.84 according to relative valuation methord.
How does RLYB's valuation metrics compare to the industry average?
The average P/S ratio for RLYB's competitors is 52.79, providing a benchmark for relative valuation. Rallybio Corp Corp (RLYB) exhibits a P/S ratio of 224.15, which is 324.60% above the industry average. Given its robust revenue growth of -29.10%, this premium appears unsustainable.
What is the current P/B ratio for Rallybio Corp (RLYB) as of Jan 10 2026?
As of Jan 10 2026, Rallybio Corp (RLYB) has a P/B ratio of 0.47. This indicates that the market values RLYB at 0.47 times its book value.
What is the current FCF Yield for Rallybio Corp (RLYB) as of Jan 10 2026?
As of Jan 10 2026, Rallybio Corp (RLYB) has a FCF Yield of -117.13%. This means that for every dollar of Rallybio Corp’s market capitalization, the company generates -117.13 cents in free cash flow.
What is the current Forward P/E ratio for Rallybio Corp (RLYB) as of Jan 10 2026?
As of Jan 10 2026, Rallybio Corp (RLYB) has a Forward P/E ratio of -1.11. This means the market is willing to pay $-1.11 for every dollar of Rallybio Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Rallybio Corp (RLYB) as of Jan 10 2026?
As of Jan 10 2026, Rallybio Corp (RLYB) has a Forward P/S ratio of 224.15. This means the market is valuing RLYB at $224.15 for every dollar of expected revenue over the next 12 months.